These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35233298)

  • 1. Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials.
    Babkoor AA; Aljabri Y; Alzubaidi A; Alhazmi R; Alsaedi Z; Alghamdi F; Tamim T; Aldagani A; Seddiqi I; Tashkandi E
    Cureus; 2022 Jan; 14(1):e21560. PubMed ID: 35233298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
    Ruiz-Schutz VC; Gomes LM; Mariano RC; de Almeida DVP; Pimenta JM; Dal Molin GZ; Kater FR; Yamamura R; Correa Neto NF; Maluf FC; Schutz FA
    Crit Rev Oncol Hematol; 2019 Sep; 141():163-173. PubMed ID: 31306986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
    Hristovska AM; Duch P; Allingstrup M; Afshari A
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012763. PubMed ID: 28806470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.
    Yin X; Yin Y; Shen C; Chen H; Wang J; Cai Z; Chen Z; Zhang B
    Onco Targets Ther; 2018; 11():6405-6414. PubMed ID: 30323618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
    Moreira RB; Debiasi M; Francini E; Nuzzo PV; Velasco G; Maluf FC; Fay AP; Bellmunt J; Choueiri TK; Schutz FA
    Oncotarget; 2017 Oct; 8(48):84572-84578. PubMed ID: 29137449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
    Gao S; Ma JJ; Lu C
    Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
    Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
    Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telephone interventions for symptom management in adults with cancer.
    Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
    Zhan P; Wang Q; Qian Q; Yu LK
    Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.